Yıl: 2024 Cilt: 35 Sayı: 2 Sayfa Aralığı: 125 - 135 Metin Dili: İngilizce DOI: 10.5152/tjg.2024.22739 İndeks Tarihi: 10-06-2024

A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose

Öz:
Background/Aims: Nonalcoholic fatty liver disease is considered as the hepatic manifestation of metabolic syndrome. Detection of circulating exosomes together with metabolomic analysis of their cargo would provide early signals for metabolic derangements and complications associated with nonalcoholic fatty liver disease. Therefore, this study profiled exosomal metabolome of patients with nonalcoholic fatty liver disease and impaired fasting glucose. Materials and Methods: Plasma exosomes were extracted from nonalcoholic fatty liver disease patients with or without impaired fast- ing glucose through differential ultracentrifugation. Their metabolite profiles were examined by ultrahigh-performance liquid chrom atography–quadrupole time-of-flight mass spectrometry. Pathway analysis was carried out on platform MetaboAnalyst 4.0. Results: Thirty-nine patients were enrolled, including nonalcoholic fatty liver disease-alone group (n = 26) and age-and gender-comparable nonalcoholic fatty liver disease plus impaired fasting glucose group (n = 13). Although less than and different from their plasma counterparts, a total of 10 significantly differential exosomal metabolites were identified. Nonalcoholic fatty liver disease plus impaired fasting glucose group had higher concentrations of linoleic acid, palmitamide, stearamide, and oleamide, as well as a lower concentration of phosphatidylethanol- amine [20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)]. Pathway analysis showed an obviously changed metabolism of linoleic acid. Conclusion: Metabolomic analysis of plasma exosomes revealed a distinct change in fatty acids and related pathways in nonalcoholic fatty liver disease patients with impaired fasting glucose. These preliminary results provide a metabolomic snapshot and basis for fur- ther investigation of exosome biology for these patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-ana- lytic assessment of prevalence, incidence, and outcomes. Hepatol- ogy. 2016;64(1):73-84. [CrossRef]
  • 2. Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999- 2014.e1. [CrossRef]
  • 3. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikra- muddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020; 323(12):1175-1183. [CrossRef]
  • 4. Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and pathological events involved in the pathogenesis of diabetes-associated nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(5):607-618. [CrossRef]
  • 5. Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of predia- betes and diabetes and metabolic profile of patients with nonalco- holic fatty liver disease (NAFLD). Diabetes Care. 2012;35(4):873-878. [CrossRef]
  • 6. Buysschaert M, Bergman M. Definition of prediabetes. Med Clin North Am. 2011;95(2):289-297. [CrossRef]
  • 7. Yilmaz Y, Senates E, Yesil A, Ergelen R, Colak Y. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J Dia- betes Complications. 2014;28(3):328-331. [CrossRef]
  • 8. Pelusi S, Cespiati A, Rametta R, et al. Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(11):2310-2319. e6. [CrossRef]
  • 9. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Predia- betes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-2290. [CrossRef]
  • 10. Johnson JL, Duick DS, Chui MA, Aldasouqi SA. Identifying predia- betes using fasting insulin levels. Endocr Pract. 2010;16(1):47-52. [CrossRef]
  • 11. Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest. 2019;129(10):4041-4049. [CrossRef]
  • 12. Kalluri R, LeBleu VS. The biology, function, and biomedical appli- cations of exosomes. Science. 2020;367(6478):eaau6977. [CrossRef]
  • 13. Newman LA, Sorich MJ, Rowland A. Role of extracellular vesicles in the pathophysiology, diagnosis and tracking of non-alcoholic fatty liver disease. J Clin Med. 2020;9(7):2032. [CrossRef]
  • 14. Hernández A, Arab JP, Reyes D, et al. Extracellular vesicles in NAFLD/ALD: from pathobiology to therapy. Cells. 2020;9(4):817. [CrossRef]
  • 15. Julich H, Willms A, Lukacs-Kornek V, Kornek M. Extracellular vesi- cle profiling and their use as potential disease specific biomarker. Front Immunol. 2014;5:413. [CrossRef]
  • 16. Williams C, Palviainen M, Reichardt NC, Siljander PR, Falcón- Pérez JM. Metabolomics applied to the study of extracellular vesicles. Metabolites. 2019;9(11):276. [CrossRef]
  • 17. Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017;25(1):43-56. [CrossRef]
  • 18. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and man- agement of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. [CrossRef]
  • 19. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S13-S27. [CrossRef]
  • 20. Coumans FAW, Brisson AR, Buzas EI, et al. Methodological guide- lines to study extracellular vesicles. Circ Res. 2017;120(10):1632- 1648. [CrossRef]
  • 21. Royo F, Théry C, Falcón-Pérez JM, Nieuwland R, Witwer KW. Methods for separation and characterization of extracellular vesi- cles: results of a worldwide survey performed by the ISEV rigor and standardization subcommittee. Cells. 2020;9(9):1955. [CrossRef]
  • 22. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position state- ment of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7(1):1535750. [CrossRef]
  • 23. Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentra- tions are associated with histologic improvement. Obes Surg. 2006;16(10):1278-1286. [CrossRef]
  • 24. Nguyen QM, Srinivasan SR, Xu JH, et al. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa Heart Study. Diabetes Care. 2011;34(12):2603-2607. [CrossRef]
  • 25. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194-1198. [CrossRef]
  • 26. Hameed A, Mojsak P, Buczynska A, Suleria HAR, Kretowski A, Ciborowski M. Altered metabolome of lipids and amino acids species: a source of early signature biomarkers of T2DM. J Clin Med. 2020;9(7):2225. [CrossRef]
  • 27. Skotland T, Sandvig K, Llorente A. Lipids in exosomes: current knowledge and the way forward. Prog Lipid Res. 2017;66:30-41. [CrossRef]
  • 28. Chen S, Datta-Chaudhuri A, Deme P, et al. Lipidomic characteri- zation of extracellular vesicles in human serum. J Circ Biomark. 2019;8:1849454419879848. [CrossRef]
  • 29. Divito EB, Cascio M. Metabolism, physiology, and analyses of primary fatty acid amides. Chem Rev. 2013;113(10):7343-7353. [CrossRef]
  • 30. Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066. [CrossRef]
  • 31. Vangaveti V, Baune BT, Kennedy RL. Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and athero- genesis. Ther Adv Endocrinol Metab. 2010;1(2):51-60.
  • 32. Burns JL, Nakamura MT, Ma DWL. Differentiating the biological effects of linoleic acid from arachidonic acid in health and disease. Prostaglandins Leukot Essent Fatty Acids. 2018;135:1-4. [CrossRef]
  • 33. Maciejewska D, Ossowski P, Drozd A, et al. Metabolites of ara- chidonic acid and linoleic acid in early stages of non-alcoholic fatty liver disease--a pilot study. Prostaglandins Other Lipid Mediat. 2015;121(B):184-189. [CrossRef]
  • 34. Feldstein AE, Lopez R, Tamimi TA, et al. Mass spectrometric pro- filing of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51(10): 3046-3054. [CrossRef]
  • 35. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 diabetes associated changes in the plasma non-esterified fatty acids,oxylipinsandendocannabinoids.PLOSONE.2012;7(11):e48852. [CrossRef]
  • 36. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol. 2004;24(9):1542- 1548. [CrossRef]
  • 37. Kumar A, Sundaram K, Mu J, et al. High-fat diet-induced upregu- lation of exosomal phosphatidylcholine contributes to insulin resist- ance. Nat Commun. 2021;12(1):213. [CrossRef]
  • 38. Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016;57(12):2099-2114. [CrossRef]
  • 39. Han X. Lipidomics for studying metabolism. Nat Rev Endocrinol. 2016;12(11):668-679. [CrossRef]
APA Jiang W, Jin Q, Li C, XUN y (2024). A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. , 125 - 135. 10.5152/tjg.2024.22739
Chicago Jiang Weiyun,Jin Qiaofei,Li Chunqing,XUN yunhao A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. (2024): 125 - 135. 10.5152/tjg.2024.22739
MLA Jiang Weiyun,Jin Qiaofei,Li Chunqing,XUN yunhao A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. , 2024, ss.125 - 135. 10.5152/tjg.2024.22739
AMA Jiang W,Jin Q,Li C,XUN y A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. . 2024; 125 - 135. 10.5152/tjg.2024.22739
Vancouver Jiang W,Jin Q,Li C,XUN y A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. . 2024; 125 - 135. 10.5152/tjg.2024.22739
IEEE Jiang W,Jin Q,Li C,XUN y "A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose." , ss.125 - 135, 2024. 10.5152/tjg.2024.22739
ISNAD Jiang, Weiyun vd. "A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose". (2024), 125-135. https://doi.org/10.5152/tjg.2024.22739
APA Jiang W, Jin Q, Li C, XUN y (2024). A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. Turkish Journal of Gastroenterology, 35(2), 125 - 135. 10.5152/tjg.2024.22739
Chicago Jiang Weiyun,Jin Qiaofei,Li Chunqing,XUN yunhao A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. Turkish Journal of Gastroenterology 35, no.2 (2024): 125 - 135. 10.5152/tjg.2024.22739
MLA Jiang Weiyun,Jin Qiaofei,Li Chunqing,XUN yunhao A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. Turkish Journal of Gastroenterology, vol.35, no.2, 2024, ss.125 - 135. 10.5152/tjg.2024.22739
AMA Jiang W,Jin Q,Li C,XUN y A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. Turkish Journal of Gastroenterology. 2024; 35(2): 125 - 135. 10.5152/tjg.2024.22739
Vancouver Jiang W,Jin Q,Li C,XUN y A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose. Turkish Journal of Gastroenterology. 2024; 35(2): 125 - 135. 10.5152/tjg.2024.22739
IEEE Jiang W,Jin Q,Li C,XUN y "A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose." Turkish Journal of Gastroenterology, 35, ss.125 - 135, 2024. 10.5152/tjg.2024.22739
ISNAD Jiang, Weiyun vd. "A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose". Turkish Journal of Gastroenterology 35/2 (2024), 125-135. https://doi.org/10.5152/tjg.2024.22739